Related Experiment Video
Updated: Mar 19, 2026
Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
Published on: April 16, 2019
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P Marso1, Gilbert H Daniels1, Kirstine Brown-Frandsen1
1From the University of Texas Southwestern Medical Center, Dallas (S.P.M.); Massachusetts General Hospital, Boston (G.H.D.); Novo Nordisk, Bagsvaerd, Denmark (K.B.-F., P.K., L.S.R., M.S.); Friedrich Alexander University of Erlangen, Erlangen (J.F.E.M.), and St. Josef Hospital, Ruhr University, Bochum (M.A.N.) - both in Germany; Cleveland Clinic, Cleveland (S.E.N.); London School of Hygiene and Tropical Medicine Medical Statistics Unit (S.P.) and Imperial College London (N.R.P.), London; George Washington University Medical Center, Washington, DC (W.M.S.); Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto (B.Z.); International Diabetes Center at Park Nicollet, Minneapolis (R.M.B.); and the University of North Carolina School of Medicine, Chapel Hill (J.B.B.).
Liraglutide significantly reduced cardiovascular events in type 2 diabetes patients. This glucagon-like peptide-1 analogue demonstrated superiority over placebo in preventing major adverse cardiovascular events.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Cardiovascular disease is a leading cause of mortality in patients with type 2 diabetes.
- The cardiovascular effects of glucagon-like peptide-1 (GLP-1) receptor agonists, such as liraglutide, are of significant clinical interest.
- Previous studies have not fully elucidated the cardiovascular benefits of liraglutide in this high-risk population.
Purpose of the Study:
- To evaluate the cardiovascular safety and efficacy of liraglutide when added to standard care in patients with type 2 diabetes and high cardiovascular risk.
- To determine if liraglutide is noninferior to placebo in reducing the incidence of major adverse cardiovascular events.
Main Methods:
- A large-scale, double-blind, randomized controlled trial (LEADER trial) involving 9340 patients with type 2 diabetes and high cardiovascular risk.
- Patients were assigned to receive either liraglutide or placebo, in addition to their standard care.
- The primary composite endpoint was the time to first occurrence of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke, analyzed using time-to-event methods.
Main Results:
- Liraglutide significantly reduced the primary composite outcome compared to placebo (hazard ratio, 0.87; P=0.01 for superiority).
- Cardiovascular death rates were significantly lower in the liraglutide group (4.7% vs. 6.0%; P=0.007).
- All-cause mortality was also significantly reduced with liraglutide (8.2% vs. 9.6%; P=0.02).
Conclusions:
- Liraglutide, when added to standard care, significantly reduces the risk of major adverse cardiovascular events and all-cause mortality in patients with type 2 diabetes and high cardiovascular risk.
- The study met its primary hypothesis, demonstrating that liraglutide is not only noninferior but also superior to placebo in reducing cardiovascular events.
- Gastrointestinal events were the most common adverse events leading to discontinuation, while pancreatitis incidence was similar between groups.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
01:22Diabetes Mellitus: Type 2 and Gestational
01:06Oral Hypoglycemic Agents: Glinides
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
01:16Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:23Dipeptidyl Peptidase 4 Inhibitors